The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hohlfeld, R.
Right arrow Articles by Toyka, K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hohlfeld, R.
Right arrow Articles by Toyka, K. V.

The Journal of Immunology, Vol 135, Issue 4 2393-2399, Copyright © 1985 by American Association of Immunologists


ARTICLES

Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis

R Hohlfeld, B Conti-Tronconi, I Kalies, J Bertrams and KV Toyka

Human autoreactive helper T lymphocytes with specificity for acetylcholine receptor (AChR) were isolated from three HLA-DR3-positive patients who had myasthenia gravis (MG), an autoimmune disease known to be associated with HLA-DR3 in the North European population. The antigen-specific T cells were evaluated for genetic restriction. Antigen presentation studies were performed with mitomycin C-treated accessory cells from a panel of HLA-typed unrelated donors. AChR- induced proliferation of the autoreactive T cells was maximal in the presence of autologous or HLA-DR-compatible antigen-presenting cells. In two DR-heterozygous patients both parental DR specificities served as restriction elements of the polyclonal AChR-reactive T cell populations. Preferential restriction to HLA-DR3 was observed in one patient, but this was also seen with PPD-specific T cells from the same donor. A series of monoclonal antibodies against HLA class II molecules was used for inhibition experiments. The inhibitory effects of the antibodies were not due to unspecific toxicity and could be observed after separate treatment of the antigen-presenting cells but not of the responding T cells. Several monoclonal antibodies against monomorphic HLA-DR determinants (DA 231, MAS 53, MAS 54, L243, OKIa1) had pronounced inhibitory effects. Anti-HLA-DQ(DC) monoclonal antibodies (Leu-10; TU 22) had only mild or no inhibitory effects in two patients but significantly inhibited AChR-specific T cells in one patient. A monoclonal antibody against HLA-DR3 (antibody 16.23) was not or was only weakly inhibitory in the DR3-positive patients, although it bound to autologous T line cells and B cells by indirect immunofluorescence. In one patient it was possible to compare the inhibition patterns of AChR-specific and PPD-specific T cells. Most of the monoclonal antibodies affected AChR- and PPD-specific T cells to a similar extent, but three antibodies (TU 22, 36, 39) inhibited PPD-specific T cells more than AChR-specific T cells, indicating the possibility of differential restriction of antigen- and autoantigen-specific T cells. It is suggested that the in vitro system described here may be helpful for the evaluation of anti-HLA class II antibodies as potential immunotherapeutic reagents.


This article has been cited by other articles:


Home page
J. Immunol.Home page
H. Yang, M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss
Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis
J. Immunol., February 1, 2005; 174(3): 1729 - 1737.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Tuzun, B. G. Scott, H. Yang, B. Wu, E. Goluszko, M. Guigneaux, S. Higgs, and P. Christadoss
Circulating Immune Complexes Augment Severity of Antibody-Mediated Myasthenia Gravis in Hypogammaglobulinemic RIIIS/J Mice
J. Immunol., May 1, 2004; 172(9): 5743 - 5752.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Tuzun, B. G. Scott, E. Goluszko, S. Higgs, and P. Christadoss
Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis
J. Immunol., October 1, 2003; 171(7): 3847 - 3854.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Deng, E. Goluszko, E. Tuzun, H. Yang, and P. Christadoss
Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production
J. Immunol., July 15, 2002; 169(2): 1077 - 1083.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Deng, E. Goluszko, and P. Christadoss
Fas/Fas Ligand Pathway, Apoptosis, and Clonal Anergy Involved in Systemic Acetylcholine Receptor T Cell Epitope Tolerance
J. Immunol., March 1, 2001; 166(5): 3458 - 3467.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1985 by The American Association of Immunologists, Inc. All rights reserved.